Valeant Pharmaceuticals International (NYSE: VRX) will sell its Asia Pacific operations to Invida Pharmaceutical Holdings Pte. Ltd. for a one-time cash payment of $37.8 million. Invida will now be able to market a portfolio of 230 former Valeant products to 12 Asian countries, including Singapore, the Philippines, Taiwan, Korea, and China. Invida, which is located in Singapore, is a holding company whose divisions include Pharmalink, a pharmaceutical and healthcare commercialization provider in the Asia Pacific region, and Inovail, a pharma focused on dermatology, complementary oncology and female healthcare. More details...